January 7, 2025 03:33 PM EST
Deals

Sanofi part­ners with Al­loy Ther­a­peu­tics to make new CNS drug

Lei Lei Wu

News Reporter

Sanofi has en­list­ed drug dis­cov­ery com­pa­ny Al­loy Ther­a­peu­tics to de­vel­op an an­ti­sense oligonu­cleotide drug for a sin­gle, undis­closed cen­tral ner­vous sys­tem tar­get.

Sanofi will pay …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

A service from the Financial Times